<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00815893</url>
  </required_header>
  <id_info>
    <org_study_id>KMUHIRB-96-09-02</org_study_id>
    <nct_id>NCT00815893</nct_id>
  </id_info>
  <brief_title>The Feasibility of Dexmedetomidine for Awake Fiberoptic Nasal Intubation</brief_title>
  <official_title>Interventional Study of Dexmedetomidine for Sedating Anticipated Difficult Airway Patients Undergoing Awake Fiberoptic Nasal Intubation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kaohsiung Medical University Chung-Ho Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kaohsiung Medical University Chung-Ho Memorial Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the feasibility of dexmedetomidine infusion for
      oral cancer patients undergoing awake fiberoptic nasal intubation. We hypothesized that a
      loading dose of intravenous dexmedetomidine before awake fiberoptic nasal intubation for oral
      cancer patients undergoing general anesthesia will provide adequate sedation and analgesia
      without respiratory depression and upper airway obstruction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Case number: 60, ASA I-III oral cancer patients with limited mouth opening

      Patients will be randomly allocated into three groups, Dex group received dexmedetomidine
      (1.0 mcg/kg) infusion, Control group received saline, and Propofol group received 1% Propofol
      administrated usng effect-site TCI.

      Main outcome was evaluated by grading scores presenting conditions for nasal intubation,
      post-intubation and satisfaction.

      Other analysed parameters included airway obstruction, hemodynamic changes, treatment for
      hemodynamics response, consumption time for intubation, amnesia level, and postoperative
      adverse events. All outcome measurements were classified by scoring systems.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2008</start_date>
  <completion_date type="Anticipated">August 2009</completion_date>
  <primary_completion_date type="Anticipated">August 2009</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>grading scores presenting conditions for nasal intubation</measure>
    <time_frame>before and after intubation</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Awake Fiberoptic Nasal Intubation</condition>
  <arm_group>
    <arm_group_label>1 dex group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>received dexmedetomidine (1.0 mcg/kg) infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2 control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>received 0.9% saline</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3 Propofol group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>received 1% propofol using effect-site TCI(Base Primea, Fresenius, France)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexmedetomidine</intervention_name>
    <description>dexmedetomidine 1.0 mcg/kg infusion for 10minutes</description>
    <arm_group_label>1 dex group</arm_group_label>
    <other_name>Precedex 100microg/ml</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal Saline 0.9%</intervention_name>
    <description>0.9% Normal Saline 0.25ml/kg infusion for 10minues</description>
    <arm_group_label>2 control group</arm_group_label>
    <other_name>saline 0.9% Nacl</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>propofol 1%</intervention_name>
    <description>Propofol: The initial target = 3 μg/ml. The TCI is adjusted by 0.5μg/ml according to patient comfort during the procedure.
The Orchestra® Base Primea(Fresenius, Brezins, France) offers a Target Controlled Infusion (TCI) target controlled infusion.</description>
    <arm_group_label>3 Propofol group</arm_group_label>
    <other_name>propofol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Head and neck cancer patients with limited mouth opening

          -  Undergoing awake fiberoptic nasal intubation for elective surgery

        Exclusion Criteria:

          -  a history of severe bradycardia

          -  any type of A-V block in EKG

          -  heart failure

          -  liver cirrhosis

          -  thrombocytopenia

          -  coagulopathy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Koung-Shing Chu, Master</last_name>
    <role>Study Director</role>
    <affiliation>Kaohsiung Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Koung-Shing Chu, Master</last_name>
    <phone>886-7-3121101</phone>
    <phone_ext>7035</phone_ext>
    <email>cks0708@ms.kmuh.org.tw</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cheng-Jing Tsai</last_name>
    <phone>886-7-3121131</phone>
    <phone_ext>7033</phone_ext>
    <email>t8501107@yahoo.com.tw</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kaohsiung Medical University Chung-Ho Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>807</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Koung-Shing Chu, Master</last_name>
      <phone>886-7-3121101</phone>
      <phone_ext>7035</phone_ext>
      <email>cks0708@ms.kmuh.org.tw</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>December 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 10, 2008</study_first_submitted>
  <study_first_submitted_qc>December 30, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 31, 2008</study_first_posted>
  <last_update_submitted>July 27, 2009</last_update_submitted>
  <last_update_submitted_qc>July 27, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2009</last_update_posted>
  <responsible_party>
    <name_title>Koung-Shing Chu</name_title>
    <organization>Department of Anesthesiology, Kaohsiung Medical University Chung-Ho Hospital</organization>
  </responsible_party>
  <keyword>Dexmedetomidine</keyword>
  <keyword>Fiberoptic nasal intubation</keyword>
  <keyword>satisfaction</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

